Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said it decided to end the development program for orteronel (TAK-700) in prostate cancer following results from two phase III studies in metastatic, castration-resistant disease in which the drug, in combination with prednisone, was found to extend progression-free survival but not overall survival.